Leading Article

OTC medicines—are they ‘open to criticism’?

Paul Turner

Department of Clinical Pharmacology, St. Bartholomew’s Hospital, London EC1A 7BE, UK.

There are three categories of medicine in terms of their availability to the public; (a) prescription only (POM), which can only be obtained on a medical or dental prescription; (b) pharmacy only (P), which do not require such a prescription, but can only be purchased in a pharmacy under the supervision of a registered pharmacist; and (c) medicines on the General Sales List, which are available, usually in restricted quantities, through other non-pharmacy retail outlets. In the United Kingdom only the first and third of these categories are legally defined. Any drug or preparation which is not included within them falls into the pharmacy-only list. Medicines available in the second and third categories are often referred to as ‘over-the-counter’ or OTC medicines.

A major determinant of the status of a medicine is its safety record, determined by its therapeutic ratio, and in countries with vigilant drug regulatory authorities OTC medicines generally have a reasonable safety record. For example, ibuprofen, the non-steroidal anti-inflammatory analgesic drug, was a recent addition to the OTC market in the United Kingdom. Experience during 14 years of prescription-only availability had shown it to be of low toxicity both generally and in overdose. During the first 2 years following its introduction in August 1983 as an OTC analgesic there was, perhaps not surprisingly, a marked increase in enquiries to the National Poisons Information Service concerning ibuprofen overdose, but no evidence of a concurrent increase in severity of poisoning from it. This confirms the results of surveys conducted in the USA where ibuprofen was granted an OTC licence in 1984.

As might be expected, pharmacists and the pharmaceutical industry wish to see an extension of the OTC drug market by a reduction in the number available only on prescription. Some clinicians have also suggested that it would be appropriate to grant some more drugs OTC status. There has been controversy in the medical journals between distinguished dermatologists on whether topical hydrocortisone preparations should be sold directly to the patient under supervision of a pharmacist. It has also been suggested by a British authority on sleep that a benzodiazepine hypnotic could safely be made available over the counter in a pharmacy.

However, while the safety record of OTC medicines in this country is not a cause for major concern, this is not true in all parts of the world, and vigilance is constantly required. We should proceed only cautiously towards an increase in the OTC list. Like any others which possess therapeutic efficacy, OTC medicines can produce adverse and unwanted effects, and because they are more freely available such effects may be less easily recognized. Some have marked central actions if taken in doses in excess of those recommended by the manufacturer, or even, in the case of anti-emetics such as hyoscine, in therapeutic doses. If taken without supervision by patients already receiving centrally acting drugs, dangerous summations of effects may occur. For example, Contac capsules, possessing both central nervous depressant and anticholinergic properties, can summate with other drugs possessing similar pharmacological properties such as tricyclic antidepressant drugs, to produce delirium and severe behavioural disorders. Drug abusers have tried to exploit the central actions of OTC medicines such as cyclizine as alternatives to less readily available drugs.

Herbal remedies are generally available without supervision, although the Medicines (Retail Sale or Supply of Herbal Remedies) Order 1977 brought the sale and supply of certain potent herbals under the control of pharmacists. Many, however, are capable of producing adverse reactions, and clinicians should always bear in mind the possibility that ingestion of such non-prescribed remedies might contribute to the clinical problem with which their patients present.

Two reports of adverse effects from OTC medicines are published in this issue. Benylin is a popular and widely used expectorant even though it is no longer prescribable on National Health Service prescriptions and its use is discouraged by the British National Formulary. Most clinicians probably regard its major adverse effects as central nervous depression or
dependence from its content of diphenhydramine, and this is reinforced by its accompanying 'label for dispensed medicines' recommended by the British National Formulary; 'May cause drowsiness. If affected do not drive or operate machinery. Avoid alcoholic drink.' However, the case report by MacRury & Neilson shows that other more subtle metabolic effects can occur in patients who take large quantities of this ammonium chloride-containing mixture over long periods of time.

Few clinicians know that kaolin and morphine mixture contains sufficient liquid liquorice extract as a flavouring agent together with sodium bicarbonate to produce unwanted effects. Hypokalaemia from excessive liquorice ingestion has been well documented, and this journal reported a woman who over 2–3 years intermittently took small amounts of medicine containing equal quantities of liquorice liquid extract B.P., cascara elixir B.P., and liquid paraffin, B.P., and presented with a flaccid quadriplegia due to profound hypokalaemia. Another paper reported a patient who died from extensive myocardial necrosis associated with prolonged hypokalaemia due to abuse of kaolin and morphine mixture. Potentially severe adverse effects can be produced by eating large quantities of apparently harmless liquorice or pentafract cakes, readily available from unsupervised sources. This present case reminds us that the non-therapeutic components of medicines, used for their flavouring or other properties, may not be inert but possess important properties with unwanted effects. Furthermore, it illustrates that a complete drug history should include all OTC remedies and favourite confectionary as part of the routine documentation of patients coming under our care.

References

OTC medicines--are they 'open to criticism'?

P. Turner

Postgrad Med J 1987 63: 519-520
doi: 10.1136/pgmj.63.741.519

Updated information and services can be found at:
http://pmj.bmj.com/content/63/741/519.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/